Daraxonrasib Doubles Pancreatic Cancer Survival | Charleston News

Pancreatic cancer patients are getting a lifeline thanks to daraxonrasib, a breakthrough drug that doubled survival time in trials—from 6.6 to over 13 months. Targeting the KRAS mutation present in 90% of cases, it’s the first direct attack on this long-elusive driver, sparking standing ovations and tears among doctors who’ve seen little progress for decades. Beyond extending life, it may soon enable surgeries or prevent recurrence. Already available via FDA-approved expanded access, this could be the dawn of a new era in fighting one of medicine’s toughest cancers.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
[email protected]

This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].

View sources & latest updates:
https://sources.thednn.ai/937b0e54f95095d4